This study demonstrates the development of a recombinant Newcastle disease virus with a porcine a1,3GT gene (NDV-GT), which triggers hyperacute rejection. The researchers successfully showed its potential in preclinical studies, including CRISPR-mediated hepatocellular carcinoma monkey models. In an interventional clinical trial with 20 patients suffering from relapsed/refractory metastatic cancer, NDV-GT demonstrated a high disease control rate (90%) and durable responses, with no serious adverse events or clinically significant neutralizing antibodies. This suggests minimal immunogenicity under these conditions and supports the feasibility of NDV-GT for immunovirotherapy. Overall, the study highlights the safety and effectiveness of intravenous NDV-GT, offering an innovative approach for oncolytic virus therapy in cancer treatment and beyond.
（“NDViraFlex” is our first "Hyperacute Immune Response New Castle Disease Virus Oncolytic Virus Customization Platform" developed based on the principle of the "NDV-GT" oncolytic virus.）